These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 7522466)

  • 21. CD28/B7 regulation of autoimmune diabetes.
    Herold KG; Lenschow DJ; Bluestone JA
    Immunol Res; 1997 Feb; 16(1):71-84. PubMed ID: 9048209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase.
    Li XL; Sluijter M; Doorduijn EM; Kale SP; McFerrin H; Liu YY; Li Y; Mottamal M; Yao X; Du F; Gu B; Hoang K; Nguyen YH; Taylor N; Stephens CR; van Hall T; Zhang QJ
    PLoS One; 2014; 9(11):e108192. PubMed ID: 25383875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cell receptor signaling can directly enhance the avidity of CD28 ligand binding.
    Sanchez-Lockhart M; Rojas AV; Fettis MM; Bauserman R; Higa TR; Miao H; Waugh RE; Miller J
    PLoS One; 2014; 9(2):e89263. PubMed ID: 24586641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen.
    Hayden MS; Grosmaire LS; Norris NA; Gilliland LK; Winberg G; Tritschler D; Tsu TT; Linsley PS; Mittler RS; Senter PD; Fell HP; Ledbetter JA
    Tissue Antigens; 1996 Oct; 48(4 Pt 1):242-54. PubMed ID: 8946677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The CD28/B7 pathway: a novel regulator of plasma cell function.
    Njau MN; Jacob J
    Adv Exp Med Biol; 2013; 785():67-75. PubMed ID: 23456839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T cells: A proliferation of costimulatory molecules.
    Mueller DL
    Curr Biol; 2000 Mar; 10(6):R227-30. PubMed ID: 10744968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FcR cross-linking on monocytes results in impaired T cell stimulatory capacity.
    Barcy S; Wettendorff M; Leo O; Urbain J; Kruger M; Ceuppens JL; de Boer M
    Int Immunol; 1995 Feb; 7(2):179-89. PubMed ID: 7537534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of B7-1 and B7-2 on the costimulation of mouse nonspecific cytotoxic T lymphocyte development in response to anti-CD3 antibody.
    Makrigiannis AP; Musgrave BL; Hoskin DW
    J Leukoc Biol; 1999 Nov; 66(5):792-802. PubMed ID: 10577511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of experimental blood stage malaria through blockade of the B7/CD28 T-cell costimulatory pathway.
    Taylor-Robinson AW; Smith EC
    Immunology; 1999 Mar; 96(3):498-504. PubMed ID: 10233733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The CD28-B7 costimulatory pathway and its role in autoimmune disease.
    Daikh D; Wofsy D; Imboden JB
    J Leukoc Biol; 1997 Aug; 62(2):156-62. PubMed ID: 9261329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD28-B7 T-cell co-stimulatory blockade potentiates the effects of intrathymic immunomodulation in sensitized graft recipients.
    Stadlbauer TH; Schaub M; Korom S; Onodera K; Sayegh MH; Kupiec-Weglinski JW
    Transplantation; 1997 Dec; 64(12):1816-22. PubMed ID: 9422425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A co-stimulatory role for CD28 in the activation of CD4+ T lymphocytes by staphylococcal enterotoxin B.
    Goldbach-Mansky R; King PD; Taylor AP; Dupont B
    Int Immunol; 1992 Dec; 4(12):1351-60. PubMed ID: 1363054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential requirements of naïve and memory T cells for CD28 costimulation in autoimmune pathogenesis.
    Perrin PJ; Lovett-Racke A; Phillips SM; Racke MK
    Histol Histopathol; 1999 Oct; 14(4):1269-76. PubMed ID: 10506942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pathway of costimulation that prevents anergy in CD28- T cells: B7-independent costimulation of CD1-restricted T cells.
    Behar SM; Porcelli SA; Beckman EM; Brenner MB
    J Exp Med; 1995 Dec; 182(6):2007-18. PubMed ID: 7500046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD28/CTLA4 double deficient mice demonstrate crucial role for B7 co-stimulation in the induction of allergic lower airways disease.
    Deurloo DT; van Berkel MA; van Esch BC; Hofhuis F; Nijkamp FP; Oosterwegel MA; van Oosterhout AJ
    Clin Exp Allergy; 2003 Sep; 33(9):1297-304. PubMed ID: 12956753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transplantation and the CD28/CTLA4/B7 pathway.
    Alegre M; Fallarino F; Zhou P; Frauwirth K; Thistlethwaite J; Newell K; Gajewski T; Bluestone J
    Transplant Proc; 2001; 33(1-2):209-11. PubMed ID: 11266782
    [No Abstract]   [Full Text] [Related]  

  • 37. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes.
    Azuma M; Cayabyab M; Buck D; Phillips JH; Lanier LL
    J Exp Med; 1992 Feb; 175(2):353-60. PubMed ID: 1370679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.
    Freeman GJ; Gribben JG; Boussiotis VA; Ng JW; Restivo VA; Lombard LA; Gray GS; Nadler LM
    Science; 1993 Nov; 262(5135):909-11. PubMed ID: 7694363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion.
    Ueda Y; Levine BL; Huang ML; Freeman GJ; Nadler LM; June CH; Ward SG
    Int Immunol; 1995 Jun; 7(6):957-66. PubMed ID: 7577804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo.
    Krummel MF; Sullivan TJ; Allison JP
    Int Immunol; 1996 Apr; 8(4):519-23. PubMed ID: 8671638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.